Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)

PacBio Q3 revenue rises to $40.6 million as CFO Jim Gibson steps down

Mixed Impact 4 of 5 earnings Written later

PacBio reported third-quarter 2026 revenue of $40.6 million, up from $38.4 million a year earlier, and a GAAP net loss of $37.8 million, roughly flat versus $38.0 million. The company also said that CFO Jim Gibson stepped down effective November 3, 2026, with Mark Van Oene named interim CFO while a permanent search continues.

Key points

  • Q3 2026 revenue was $40.6 million versus $38.4 million in Q3 2025; GAAP gross margin fell to 33% from 41%.
  • GAAP net loss was $37.8 million, or $0.12 per share, versus $38.0 million, or $0.13 per share, a year earlier.
  • Full-year 2026 revenue is now expected to be in the range of $155 million to $160 million.
  • Ending cash, cash equivalents and investments were $199.4 million, down from $298.7 million a year earlier.

The filing

CompanyPACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:09 PM ET
Accession number0001299130-26-000133

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.